靶向PI3K信号通路抑制剂在胰腺癌治疗中的研究进展

Targeted PI3K signaling pathway inhibitors in treatment of pancreatic cancer

胰腺癌(Pancreatic Cancer,PC)作为高侵袭性恶性肿瘤,其发病率逐年上升。对于不适合手术治疗的患者,靶向治疗具有明显优势。肿瘤细胞的增殖、凋亡及血管生成等生物学行为受磷脂酰肌醇3激酶信号通路的调节,使用PI3K抑制剂可改善患者预后。目前靶向PI3K抑制剂,已在淋巴造血系统肿瘤和其它实体瘤的临床试验中取得较好结果,但在胰腺癌中研究较少。基于此,我们回顾了PI3K通路研究情况,并就靶向PI3K信号通路抑制剂在胰腺癌治疗中的新进展作一综述。

The incidence of pancreatic cancer(PC),as a highly invasive malignant tumor,is increasing both at home and abroad annually.For patients with no indication of surgical treatment,targeted therapy has obvi⁃ous advantages.The biological behaviors of tumor cells such as proliferation,apoptosis and angiogenesis are regu⁃lated by the phosphatidylinositol 3 kinase(PI3K)signaling pathway,and the use of PI3K inhibitors can improve the prognosis of patients.Inhibitors of the PI3K signaling pathway include those targeting a single component and dual or multiple inhibitors.At present,PI3K⁃targeted inhibitors have achieved good results in clinical trials of lym⁃phoid hematopoietic tumors and other solid tumors,but there are few studies on pancreatic cancer.For this reason,we briefly review the research progress of PI3K pathway,summarizing the new advances of inhibitors targeting PI3K signaling pathway in the treatment of pancreatic cancer.